[Neo-adjuvant chemotherapy with UFT and adriamycin in head and neck cancer].
Thirty-one patients with head and neck cancer were administered pretreatment induction chemotherapy (so-called neo-adjuvant chemotherapy) consisting of a UFT and ADM combination. The chemotherapy consisted of ADM (0.5 mg/kg b.w.) once a week up to 3 times, and UFT (600 mg/day) every day for 20 days. Overall response rate was 37.9% (11/31), and 1 CR and 10 PR were obtained. After definitive treatment, the primary control rate was 80.6% (25/31). Sixteen primary lesions in the 31 patients were classified according to Shimosato's grading system into 1 grade IV, 5 grade III and 10 grade II b a-I. Lymph-node metastases in 5 cases were also classified. The grading of lymph-node metastases was lower than that of the primary lesions.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D005641:Tegafur; D014498:Uracil; D004317:Doxorubicin